Skip to main content
Published in: International Urology and Nephrology 4/2024

19-11-2023 | Urology - Original Paper

Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?

Authors: Irene J. Beijert, Anouk E. Hentschel, Johannes Bründl, Eva M. Compérat, Karin Plass, Oscar Rodríguez, Jose D. Subiela Henríquez, Virginia Hernández, Enrique de la Peña, Isabel Alemany, Diana Turturica, Francesca Pisano, Francesco Soria, Otakar Čapoun, Lenka Bauerová, Michael Pešl, H. Maxim Bruins, Willemien Runneboom, Sonja Herdegen, Johannes Breyer, Antonin Brisuda, Ana Calatrava, José Rubio-Briones, Maximilian Seles, Sebastian Mannweiler, Judith Bosschieter, Venkata R. M. Kusuma, David Ashabere, Nicolai Huebner, Juliette Cotte, Roberto Contieri, Laura S. Mertens, Francesco Claps, Alexandra Masson-Lecomte, Fredrik Liedberg, Daniel Cohen, Luca Lunelli, Olivier Cussenot, Soha El Sheikh, Dimitrios Volanis, Jean-François Côté, Morgan Rouprêt, Andrea Haitel, Shahrokh F. Shariat, A. Hugh Mostafid, Jakko A. Nieuwenhuijzen, Richard Zigeuner, Jose L. Dominguez-Escrig, Jaromir Hacek, Alexandre R. Zlotta, Maximilian Burger, Matthias Evert, Christina A. Hulsbergen-van de Kaa, Antoine G. van der Heijden, Lambertus A. L. M. Kiemeney, Viktor Soukup, Luca Molinaro, Paolo Gontero, Carlos Llorente, Ferran Algaba, Joan Palou, James N’Dow, Maria J. Ribal, Theo H. van der Kwast, Marko Babjuk, Richard J. Sylvester, Bas W. G. van Rhijn

Published in: International Urology and Nephrology | Issue 4/2024

Login to get access



A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial resection, restaging-TURB is required if the first resection was macroscopically complete but contained no detrusor muscle (DM) and second-TURB is advised for all completely resected T1-tumors with DM in the resection specimen. This study assessed the long-term outcomes after repeat-, second-, and restaging-TURB in T1-NMIBC patients.


Individual patient data with tumor characteristics of 1660 primary T1-patients (muscle-invasion at re-TURB omitted) diagnosed from 1990 to 2018 in 17 hospitals were analyzed. Time to recurrence, progression, death due to bladder cancer (BC), and all causes (OS) were visualized with cumulative incidence functions and analyzed by log-rank tests and multivariable Cox-regression models stratified by institution.


Median follow-up was 45.3 (IQR 22.7–81.1) months. There were no differences in time to recurrence, progression, or OS between patients undergoing restaging (135 patients), second (644 patients), or repeat-TURB (84 patients), nor between patients who did or who did not undergo second or restaging-TURB. However, patients who underwent repeat-TURB had a shorter time to BC death compared to those who had second- or restaging-TURB (multivariable HR 3.58, P = 0.004).


Prognosis did not significantly differ between patients who underwent restaging- or second-TURB. However, a worse prognosis in terms of death due to bladder cancer was found in patients who underwent repeat-TURB compared to second-TURB and restaging-TURB, highlighting the importance of separately evaluating different indications for re-TURB.
Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
Irene J. Beijert
Anouk E. Hentschel
Johannes Bründl
Eva M. Compérat
Karin Plass
Oscar Rodríguez
Jose D. Subiela Henríquez
Virginia Hernández
Enrique de la Peña
Isabel Alemany
Diana Turturica
Francesca Pisano
Francesco Soria
Otakar Čapoun
Lenka Bauerová
Michael Pešl
H. Maxim Bruins
Willemien Runneboom
Sonja Herdegen
Johannes Breyer
Antonin Brisuda
Ana Calatrava
José Rubio-Briones
Maximilian Seles
Sebastian Mannweiler
Judith Bosschieter
Venkata R. M. Kusuma
David Ashabere
Nicolai Huebner
Juliette Cotte
Roberto Contieri
Laura S. Mertens
Francesco Claps
Alexandra Masson-Lecomte
Fredrik Liedberg
Daniel Cohen
Luca Lunelli
Olivier Cussenot
Soha El Sheikh
Dimitrios Volanis
Jean-François Côté
Morgan Rouprêt
Andrea Haitel
Shahrokh F. Shariat
A. Hugh Mostafid
Jakko A. Nieuwenhuijzen
Richard Zigeuner
Jose L. Dominguez-Escrig
Jaromir Hacek
Alexandre R. Zlotta
Maximilian Burger
Matthias Evert
Christina A. Hulsbergen-van de Kaa
Antoine G. van der Heijden
Lambertus A. L. M. Kiemeney
Viktor Soukup
Luca Molinaro
Paolo Gontero
Carlos Llorente
Ferran Algaba
Joan Palou
James N’Dow
Maria J. Ribal
Theo H. van der Kwast
Marko Babjuk
Richard J. Sylvester
Bas W. G. van Rhijn
Publication date
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584

Other articles of this Issue 4/2024

International Urology and Nephrology 4/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.